Phase III evaluable patients
721 patients
- EndpointAssociation of baseline aBSI with outcomes
- PopulationaBSI
- Tested versionaBSI version 3.4 cleared in K191262
FDA-cleared profile
EXINI Diagnostics AB · PET/SPECT/Nuclear Medicine · FDA-cleared (510(k))
Authorized purpose: aBSI analyzes nuclear-medicine whole-body bone scans and SPECT to mark lesions and quantify skeletal disease burden as a fraction of total skeletal weight for trained professionals and researchers; the cloud release does not accept CT or static partial bone scans.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: aBSI analyzes nuclear-medicine whole-body bone scans and SPECT to mark lesions and quantify skeletal disease burden as a fraction of total skeletal weight for trained professionals and researchers; the cloud release does not accept CT or static partial bone scans.
Evidence takeaway. Evidence from the reviewed source record: K191262 reports analytical, reproducibility, phantom, and two clinical studies. In a 721-patient phase III analysis, baseline aBSI was associated with overall survival and remained independently associated after adjustment; a separate 169-patient analysis found that an aBSI increase of 0.6 had the same 0.52 association with time to radiographic bone progression as PCWG criteria.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
The exact subject-device comparison provides the DICOM 3 input types and the CT/static-partial boundary.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
The exact software-risk discussion states this consequence boundary; the packet does not state the prior threshold, acquisition, urinary-activity, or standalone-diagnosis wording.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.
Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.
721 patients
1.2 hazard ratio
1.06 hazard ratio
0.52 Kendall tau
0.995 Pearson r
0.96 kappa
100 %
36.2 %
K191262
Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.
PMC4975929
Algorithm-family evidence with an earlier version; includes a documented bladder-region blind spot.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United StatesBuild a local total-cost and value model; do not infer reimbursement from FDA clearance.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: DICOM 3 whole-body bone scans and SPECT; CT images are not accepted, and static (partial) bone scans are not required or used for BSI calculation.
Scope: Exact FDA submission. The exact subject-device comparison provides the DICOM 3 input types and the CT/static-partial boundary.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-19 · FDA K191262: aBSI
Source context, not route validation: Cloud service accessed through a personal login on Windows or macOS Chrome, with image upload from a local or network folder; validate DICOM transfer, identity, patient matching, longitudinal alignment, browser support, and result export.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-03 · FDA K191262: aBSI
Source context, not route validation: Cloud-hosted software service accessed by a supported browser; exact tenancy, region, retention, identity, audit, and support controls require vendor confirmation.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-03 · FDA K191262: aBSI
Source context, not route validation: Marked hotspots, quantitative aBSI, image display, reports, and optional CSV research export.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-19 · FDA K191262: aBSI
Unresolved route: Marked hotspots, quantitative aBSI, image display, reports, and optional CSV research export.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-19 · FDA K191262: aBSI
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Confirm the controls against the exact contracted architecture and release.
Map the installed model, build, options, population, anatomy, inputs, and outputs to K191262 before acceptance.
exact submission · checked 2026-09-03Later product-family features are not evidence that this cleared release includes them.
Cloud service accessed through a personal login on Windows or macOS Chrome, with image upload from a local or network folder; validate DICOM transfer, identity, patient matching, longitudinal alignment, browser support, and result export.
exact submission · checked 2026-09-03Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. aBSI is quantitative decision support, not a standalone metastasis diagnosis. Threshold-dependent staging performance can trade sensitivity against specificity, and scan counts, acquisition speed, urinary activity, protocol, and disease burden can affect results.
exact submission · checked 2026-09-03Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-03Vendor productivity claims are scenario inputs, not guaranteed local savings.
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: aBSI is quantitative decision support, not a standalone metastasis diagnosis. Threshold-dependent staging performance can trade sensitivity against specificity, and scan counts, acquisition speed, urinary activity, protocol, and disease burden can affect results.
exact submission · checked 2026-09-03Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
The exact indication names nuclear-medicine imaging and the subject-device comparison lists DICOM 3 whole-body bone scans and SPECT; it does not support the dossier's PET wording. Controlled directory display reconciled from exact FDA wording: Nuclear medicine (NM) imaging, including DICOM 3 whole-body bone scans and SPECT. -> PET/SPECT/Nuclear Medicine.
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
The refreshed discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, peer reviewed publication, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
8 sources - 3 history items
Scope: purpose, anatomy, intendedUsers, output, evidenceSummary, modality, input, limitations, clinicalUse
Scope: regulatoryIdentity, modalityContext
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: coverage, codingContext
Scope: recallDiscovery, nativeSubmissionMatching
Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, monitoring
Scope: limitations, evidenceSummary, evidenceStudy, evidenceMetrics, monitoring
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
GE Medical Systems Israel, Functional Imaging
Authorized purpose: Clarify DL is a deep-learning reconstruction function intended to reduce noise and improve image quality of nuclear-medicine bone SPECT scintigraphy for all ages on the supported Xeleris V and StarGuide platforms.
GE Healthcare
Authorized purpose: The Xeleris V Processing and Review System displays, processes, archives, prints, reports, and networks planar, SPECT, and PET nuclear-medicine data, with optional applications for DaTQUANT, lung analysis, brain analysis, coronary-flow reserve, prostate-cancer bone metastases, liver shunt and dose calculations, and monitoring of patient radiation doses from nuclear-medicine imaging data.
Siemens Medical Solutions USA, Inc.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
GE Medical Systems Israel
Authorized purpose: Aurora is a SPECT/CT system for nuclear-medicine uptake imaging, standalone CT, anatomical localization, attenuation correction, diagnosis, staging, therapy planning, guidance, and monitoring. K251153 adds deep-learning kidney segmentation to dynamic renal scintigraphy.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history